Тирофибан Чайкафарма

Тирофибан Чайкафарма is an intravenous medication containing Tirofiban Hydrochloride Monohydrate, used for managing acute coronary syndromes. This EU-manufactured drug supports platelet inhibition in clinical settings. Always consult a healthcare provider for proper use.

Тирофибан Чайкафарма is used to prevent blood clots in patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI). It belongs to a class of drugs that inhibit platelet aggregation, helping reduce the risk of heart-related complications. This medication is typically administered in a hospital setting under medical supervision.

As an antiplatelet agent, Тирофибан Чайкафарма works by blocking platelet receptors to prevent clot formation. Patients may experience improved blood flow and reduced strain on the heart during treatment. Common effects include temporary changes in blood pressure or heart rate, which are monitored closely.

Тирофибан Чайкафарма should only be handled and administered by trained medical professionals. Patients with a history of bleeding disorders or recent major surgery may require special consideration. Regular monitoring of blood parameters is essential during therapy to ensure safety.

This medication may interact with other drugs that affect blood clotting, such as anticoagulants or nonsteroidal anti-inflammatory drugs (NSAIDs). Alcohol and certain herbal supplements can also increase bleeding risks. Always inform healthcare providers about all medications being taken before starting treatment.